The present invention is directed to a compound represented by formula (1):
(wherein R
1
represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and
each of R
2
and R
3
represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R
2
and R
3
form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-α) production inhibitory effect and improved absorption upon oral administration.
The present invention is directed to a compound represented by formula (1):
(wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and
each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-α) production inhibitory effect and improved absorption upon oral administration.